The top 100 stock
market authors
selected for publication
market authors
selected for publication
Spectrum Pharmaceuticals, Inc. (SPPI) ()
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Spectrum Pharmaceuticals, Inc. (SPPI) by latest | most commented
- FDA Calendar Updates: Rigel Pharma, GlaxoSmithKline, Eisai, SuperGen
- FDA Calendar Updates: Oxford, Protalix, Spectrum, Shire
- Spectrum: FDA News on Zevalin Equals an Approval
- Spectrum Pharmaceuticals: Temporary Setback
- Closing Update for Wednesday, July 1
- Big Lineup of Healthcare Stocks Crack the Russell 3000 Index
- Can Spectrum Pharmaceuticals Benefit from FDA Action on Zevalin?
- 17 Reasons Why Bayer Might Acquire Spectrum Pharmaceuticals
- Spectrum Pharmaceuticals: Optimistic About Zevalin's Prospects
- Today's Healthcare Market Movers: SCLN, HEB, SPPI, CRTX, KV.A
- Pending FDA Decisions: 20 Extreme Trades
- 15 Possible Healthcare Breakout Stocks
- Spectrum Pharmaceuticals: Undervalued Growth Company with Strong Late-Stage Pipeline
- FDA Calendar: 18 Hot Summer Trades
- Two Possible Upcoming Approvals for Spectrum Pharmaceuticals
- 13 Extreme FDA Trades
- Pending FDA Decisions: 12 Extreme Trades
- FDA, Clinical Trial Calendars: Nine 'Cash Plus Catalyst' Trades
- Cell Therapeutics' Turnaround Remains on Track
- Vanda Pharma: An Extreme FDA Trade That Paid; 9 More to Go
- Tracking Cancer Diagnostic and Therapeutic Stocks
- Cell Therapeutics Reemerging
- 12 Extreme FDA Trades on New Product Decisions
- FDA and Clinical Trial Updates: Osiris Sees Flaw in Crohn's Disease Trial
- Trading FDA Decisions: 14 Candidates
- Chink in the Biotechnology Armor
- Biotech FDA and Clinical Trial Calendar Update
- Cell Therapeutics Is down but Not Out
- Which Has a Better Risk/Reward Ratio - Citigroup or Cell Genesys?
- Cancer Stocks Finish a Tough Quarter
- Cancer Stocks: Tracking the Market
- Cancer Stocks: The Bleeding Slows
- Cancer Stocks Hammered Once Again
- Cancer Stocks Slide Again
- Cancer Stocks Plunge Following ASCO Meeting
- Cancer Stocks Soar With Annual ASCO Meeting
- Cancer Stocks on the Go: Winners and Losers
- Biotech Week in Review: Onyx Is Star of the Week
- Spectrum Pharmaceuticals, GPC Up Strongly on Positive Phase 3 Trials for Prostate Cancer Drug
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largest
increase in followers
in the last 7 days-
1
David Fry
-
2
Bill Gross
-
3
Philip Davis
-
4
Tyler Durden
-
5
TraderMark
Fastest Climbers » -
1
-
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
